Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials
Open Access
- 11 December 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (1) , 95-107
Abstract
Herein we detail the first disclosure of VU0467319 (VU319), an M1 Positive Allosteric Modulator (PAM) clinical candidate that successfully completed a Phase I Single Ascending Dose (SAD) clinical trial. VU319 (16) is a moderately potent M1 PAM (M1 PAM EC50 = 492 nM ± 2.9 nM, 71.3 ± 9.9% ACh Max), with minimal M1 agonism (EC50 > 30 μM), that displayed high CNS penetration (Kps > 0.67 and Kp,uus > 0.9) and multispecies pharmacokinetics permissive of further development. Based on robust efficacy in multiple preclinical models of cognition, an ancillary pharmacology profile devoid of appreciable off-target activities, and a lack of cholinergic adverse effects (AEs) in rats, dogs and nonhuman primates, VU319 advanced into IND-enabling studies. After completing 4-week rat and dog GLP toxicology without AEs, including absence of cholinergic effects, the first in human Phase I SAD clinical trial of VU319 (NCT03220295) was performed at Vanderbilt, where a similar lack of adverse effects, including absence of cholinergic effects was noted. Moreover, signals of target engagement were seen at the highest dose tested. Thus, VU319 demonstrated the feasibility of achieving selective targeting of central M1 muscarinic receptors without eliciting cholinergic AEs that have plagued other drugs targeting CNS cholinergic neurotransmission.Keywords
Funding Information
- National Institute of Mental Health (MH073676, MH082867, MH108498)
This publication has 37 references indexed in Scilit:
- Clinical and Preclinical Evidence for M1 Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett SyndromeNeurotherapeutics, 2022
- Functional activity of the muscarinic positive allosteric modulator VU319 during a Phase 1 Single Ascending Dose studyThe American Journal of Geriatric Psychiatry, 2021
- Cognitive performance effects following a single dose of the M1 muscarinic positive allosteric modulator VU319Alzheimer's & Dementia, 2020
- Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu4 positive allosteric modulators that mitigate CYP1A2 induction liabilityBioorganic & Medicinal Chemistry Letters, 2018
- The relevance of inter- and intrastrain differences in mice and rats and their implications for models of seizures and epilepsyEpilepsy & Behavior, 2017
- Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's diseaseDrug Discovery Today, 2013
- Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: Continued optimization of an MLPCN probe moleculeBioorganic & Medicinal Chemistry Letters, 2013
- Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAMBioorganic & Medicinal Chemistry Letters, 2010
- Muscarinic agonists and antagonists in the treatment of Alzheimer's diseaseIl Farmaco, 2001
- Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer DiseaseArchives of Neurology, 1997